Progress in acute myeloid leukemia

Tapan M. Kadia, Farhad Ravandi, Susan O'Brien, Jorge Cortes, Hagop M. Kantarjian

Research output: Contribution to journalReview article

27 Scopus citations

Abstract

Significant progress has been made in the treatment of acute myeloid leukemia (AML). Steady gains in clinical research and a renaissance of genomics in leukemia have led to improved outcomes. The recognition of tremendous heterogeneity in AML has allowed individualized treatments of specific disease entities within the context of patient age, cytogenetics, and mutational analysis. The following is a comprehensive review of the current state of AML therapy and a roadmap of our approach to these distinct disease entities.

Original languageEnglish (US)
Pages (from-to)139-151
Number of pages13
JournalClinical Lymphoma, Myeloma and Leukemia
Volume15
Issue number3
DOIs
StatePublished - Mar 1 2015
Externally publishedYes

    Fingerprint

Keywords

  • AML
  • Review
  • Targeted therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Kadia, T. M., Ravandi, F., O'Brien, S., Cortes, J., & Kantarjian, H. M. (2015). Progress in acute myeloid leukemia. Clinical Lymphoma, Myeloma and Leukemia, 15(3), 139-151. https://doi.org/10.1016/j.clml.2014.08.006